Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy
Dr. Park and co-panelists review the patient and disease characteristics, including patient age, high pre-apheresis disease burden, and bridging response to inotuzumab or blinatumomab among other variables that might best support consideration of post-CART19 maintenance therapy.
EP: 1.Faculty Introductions
EP: 2.Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL
EP: 3.Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL
EP: 4.Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial
EP: 5.Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease
EP: 6.Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion
EP: 7.Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)
Now Viewing
EP: 8.Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy
EP: 9.Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
EP: 10.Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia
Related Videos
Related Content
